Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

Abstract

Introduction

Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment options. Recent studies have suggested promising results for JAK1/3 inhibitors including tofacitinib and ruxolitinib.

Objective

To determine the expected response of vitiligo to JAK inhibitor therapy and factors which influence response rates.

Methods

A systematic review and meta-analysis was performed according to PRISMA guidelines. Good response was defined as repigmentation >50% or a ‘good’ or ‘excellent’ outcome as described by authors. Partial response was defined as some repigmentation <50%.

Results

From the 9 eligible studies, individual patient data from 45 cases were pooled. Good response was achieved in 57.8%, partial response in 22.2%, and none or minimal response in 20% of cases. When subgrouped according to site, facial vitiligo had the highest good response rate (70%), compared to extremities (27.3%) and torso/non-sun exposed areas (13.6%). Concurrent phototherapy was significant associated with higher rates of good overall response (p < .001) and good facial response (p < .001).

Conclusions

There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in vitiligo. Concurrent UVB phototherapy appears to improve efficacy of JAK inhibitors for vitiligo.

Keywords:

• vilitigo
• JAK inhibitors
• Janus kinase

Ethics approval

Not required as this is a systematic review.

Disclosure statement

No potential conflict of interest was reported by the author(s).